Company Profile

Weaker Buy Today ACAD ranks #1369 as BUY CANDIDATE. Stronger Buy
Today ACAD ranks #1369 as BUY CANDIDATE.

ACAD stock ACADIA Pharmaceuticals Inc.

ACAD stock
ACADIA Pharmaceuticals Inc.

ACADIA Pharmaceuticals Inc.

3611 Valley Centre Drive

San Diego, CA 92130


Industry: Biotechnology

Sector: Healthcare


ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs that address unmet medical needs in central nervous system disorders. Its lead product candidate, NUPLAZID, has completed the Phase III pivotal trials for the treatment of Parkinson’s disease psychosis and the Phase II trial for the treatment of schizophrenia, as well as is in Phase II study for the treatment of Alzheimer’s disease psychosis. It also has clinical-stage programs for glaucoma and, in collaboration with Allergan, Inc., for chronic pain. ACADIA Pharmaceuticals Inc. was founded in 1993 and is headquartered in San Diego, California.

Proudly made at

Rise Vilnius
in partnership with
Barclays Bank